4th Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

issues surrounding ADHD, including economic and social impact; binge eating disorder; drug shortages; DEA processes; FDA funding and sequester; specialty tiers; track and trace; step therapy; drug development; patent issues; H.R. 5805, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2014; Priority Review Vouchers; FDASIA implementation; ACA implementation; bundling rules for the Hospital Outpatient Prospective Payment System; CMS coding coverage; line extension rebates; Medicare Part D rebates; H.J. Res. 59, Continuing Appropriations Resolution, 2014 and possible drug industry issues; tax reform; orphan drug tax credit; R&D tax credits

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —
CARRIE BURKE New —
JOHN EDWARD GREISSING —
MARK LENKER —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1281 (113th), H.J.Res. 59 (113th), H.R. 5805 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.